Jubin Ronald
Schering-Plough Research Institute, Department of Antiviral Therapy, 2015 Galloping Hill Road, Mailstop 4945, Kenilworth, NJ 07033, USA.
Curr Opin Investig Drugs. 2003 Feb;4(2):162-7.
Hepatitis C virus (HCV) infection is an emerging global health concern. Combination therapy with pegylated interferon-alpha (INF alpha) and ribavirin results in approximately 60% sustained recovery. Of the non-responders, the majority are infected with genotype 1. As a consequence, improved therapeutics are necessary to enhance response rates, especially in genotype-1-infected individuals. HCV translation is mediated by an internal ribosome entry site (IRES) located within the 5' non-translated region. Recent studies have revealed that the HCV IRES recruits the cellular translation machinery in a distinct manner compared with cellular mRNA strategies. Therefore, screening assays can be developed to identify specific inhibitors of HCV translation as a possible treatment for HCV.
丙型肝炎病毒（HCV）感染是一个新出现的全球卫生问题。聚乙二醇化α干扰素（INFα）和利巴韦林联合治疗可使约60%的患者实现持续康复。在无应答者中，大多数感染的是1型基因型。因此，需要改进治疗方法以提高应答率，尤其是在感染1型基因型的个体中。HCV翻译由位于5'非翻译区内的内部核糖体进入位点（IRES）介导。最近的研究表明，与细胞mRNA策略相比，HCV IRES以一种独特的方式招募细胞翻译机制。因此，可以开发筛选试验来鉴定HCV翻译的特异性抑制剂，作为治疗HCV的一种可能方法。
